×

Biopharmaceutical discovery

BioSynthema Inc.

http://www.biosynthema.com

BioSynthema discovers and develops unique pharmaceuticals that are targeted to cell surface receptors overexpressed in cancer cells. The technology makes specific tumors highly visible using diagnostic imaging methods, and enables earlier and more accurate diagnosis. The technology is also applied to the treatment of cancer. BioSynthema is currently developing compounds that will bring new and effective products to the market for the diagnosis and treatment of neuroendocrine tumors.

  • 12/8/2013
  • 13
  • 0

LXR Biotechnology Inc.

http://www.lxr.com

LXR*TEST is designed to assess examinee performance on a particular exam. If you have need to assess overall examinee performance on multiple exams, then a gradebook application, such as Grade Machine 6.9, may prove useful. Because LXR*TEST 6.0 can export score data into a delimited text file, you can import such information into Grade Machine 6.9. Note: The following procedure is provided to facilitate transferring your LXR*TEST 6.0 exam scores to Grade Machine 6.9. It is known that only using the import filter of Grade Machine, by itself, is insufficient in bringing in your LXR*TEST 6.0 exam scores.

  • 12/8/2013
  • 14
  • 0

DIAGENICS International Corporation

http://www.diagenics.com

DIAGENICS is a biopharmaceutical company located in Woburn (Boston), MA (USA) with its European headquarters in Duesseldorf, Germany. Our unique business model strives to build a Bridge from Science to BusinessÔ. In this way we aspire to a leading position in the diagnostic field. We are currently focussing on the detection of heart infarction through a new and patented heartmarker. DIAGENICS constantly observes scientific results and compares them with the needs of market and economy. Thus, many promising projects are targeted, licensed and quickly developed until they are ready for the market. With DIACORDONÔ, DIAGENICS has already launched its first product line for the diagnosis of infarction. Besides the development of a sophisticated ACS biochip device DAGENICS plans to widen its supply with projects on stroke diagnosis.

  • 12/8/2013
  • 18
  • 0

Angiogenex, Inc.

  • 12/8/2013
  • 12
  • 0

Emiliem , Inc.

  • 12/8/2013
  • 17
  • 0

CereMedix , Inc.

  • 12/8/2013
  • 14
  • 0

REPLICor Inc.

  • 12/8/2013
  • 13
  • 0

ARCA Discovery , Inc.

  • 12/8/2013
  • 14
  • 0

ExSAR Corporation

  • 12/8/2013
  • 14
  • 0

APT Therapeutics Inc.

  • 12/8/2013
  • 10
  • 0

Note

Not found any data